New test provides physicians with a liquid biopsy option to reach informed treatment decisions for patients with melanoma and other tumors SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
New test uses patient's blood sample to detect KRAS, predictive biomarker for solid tumor cancers SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today
New test uses patient's blood sample to profile and monitor for PD-L1 expression, an important biomarker in immuno-oncology treatment decision makingTest developed in collaboration with renowned pathologist David Rimm, MD, PhD, of Yale University School of Medicine
Target Selector™ kits are research-use-only (RUO) and designed to enable laboratories around the world to leverage Biocept's patented assay technology to perform cutting-edge liquid biopsy testing SAN DIEGO , Jan. 28, 2019 /PRNewswire/ -- Biocept, Inc.
Expands commercial offering to 15 clinically actionable biomarker tests, including key validated alterations listed in the NCCN Guidelines® for metastatic melanoma and colorectal cancer
First and only platform that enables local pathologists to obtain molecular biomarker information from a simple blood sample using cutting-edge circulating tumor cell (CTC) technology
SAN DIEGO , April 20, 2020 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
